10-Q: Pulmonx Q3 2025: Revenue Growth Amidst Continued Losses

Pulmonx Corporation reports increased revenue in Q3 2025, driven by Zephyr Valve procedure volumes, but continues to incur significant net losses and negative cash flows from operations.

Summary

• Revenue for the three months ended September 30, 2025, increased by 5.5% to $21.5 million, compared to $20.4 million in the prior year period.
• Revenue for the nine months ended September 30, 2025, increased by 13.1% to $67.9 million, compared to $60.0 million in the prior year period.
• Net loss for the three months ended September 30, 2025, was $(14.0) million, a slight improvement from $(14.1) million in the prior year period.
• Net loss for the nine months ended September 30, 2025, was $(43.6) million, compared to $(43.2) million in the prior year period.
• Gross margin for the three months ended September 30, 2025, was 74.7%, up from 73.7% in the prior year period, primarily due to geographic mix.
• Gross margin for the nine months ended September 30, 2025, was 73.0%, down from 74.0% in the prior year period, primarily due to geographic mix and increased manufacturing costs.
• The accumulated deficit as of September 30, 2025, reached $511.1 million.
• Cash and cash equivalents stood at $76.5 million as of September 30, 2025.
• The company used $25.3 million in cash from operating activities during the nine months ended September 30, 2025.
• The interest-only period for the CIBC Loan was extended through its maturity date of October 2027.
• In October 2025, Glendon E. French was appointed President and Chief Executive Officer, and Derrick Sung, Ph.D. was appointed Chief Operating Officer and Chief Financial Officer.

Sentiment

Score: 4

Explanation: While Pulmonx demonstrated revenue growth and improved gross margin in the recent quarter, the company continues to incur substantial net losses and negative cash flow from operations, leading to a significant accumulated deficit. The extension of the CIBC loan's interest-only period provides some near-term liquidity relief, and the USDOJ's decision not to intervene in the Qui Tam action removes a significant legal overhang. However, the company explicitly states the need for substantial additional capital in the future, which could lead to further shareholder dilution. The competitive landscape, regulatory complexities, and reliance on a single primary product for a limited indication present ongoing challenges.

Positives

• Revenue increased by 5.5% for the three months and 13.1% for the nine months ended September 30, 2025, driven by continued growth in Zephyr Valve procedure volumes.
• Gross margin improved to 74.7% for the three months ended September 30, 2025, primarily due to favorable geographic mix.
• Interest expense decreased by $0.1 million for the three months and $0.3 million for the nine months due to lower interest rates.
• The CIBC Loan's interest-only period was extended through its October 2027 maturity, deferring principal repayments.
• The U.S. Department of Justice (USDOJ) elected not to intervene or pursue the Qui Tam Action further, reducing a significant legal overhang.

Negatives

• The company continues to incur significant net losses, with $(14.0) million for Q3 2025 and $(43.6) million for the nine months ended September 30, 2025.
• Negative cash flow from operations persisted, with $25.3 million used during the nine months ended September 30, 2025.
• The accumulated deficit grew to $511.1 million as of September 30, 2025.
• Interest income decreased by $0.7 million for the three months and $1.8 million for the nine months, primarily due to a lower balance of cash, cash equivalents, and marketable securities.
• Gross margin for the nine months ended September 30, 2025, decreased to 73.0% from 74.0% in the prior year, attributed to geographic mix and increased manufacturing costs.
• Research and development expenses increased by 29.4% for the three months and 9.9% for the nine months, driven by clinical trials and product development.

Risks

• The company has a history of significant net losses, which are expected to continue, and there is no assurance of achieving or sustaining profitability in the future.
• Limited experience marketing and selling its solution, relying on a single product (Zephyr Valve) for limited indications, could negatively affect business if commercialization is unsuccessful.
• Business is dependent on hospital, physician, and patient adoption of the solution, and unwillingness to change current practices could negatively affect results.
• Failure to receive access to hospital facilities through purchasing contracts or bidding processes could decrease sales and harm operating results.
• Use of the Zephyr Valve involves risks and may result in complications, including pneumothorax or death, and is contraindicated in certain patients, which may limit adoption.
• Inability to achieve and maintain adequate levels of coverage or reimbursement for the solution, or if patients face significant out-of-pocket costs, could severely hinder commercial success.
• Failure to retain marketing and sales personnel, or to increase capabilities and develop broad awareness cost-effectively, may prevent revenue growth.
• Limited long-term data regarding the safety and effectiveness of products, including the Zephyr Valve, may hinder acceptance.
• Limited experience manufacturing products in significant commercial quantities and facing manufacturing risks could adversely affect ability to manufacture, reduce gross margins, and negatively affect results.
• Compromised information technology systems or data, or those of third parties, could lead to operational interruptions, data breaches, reputational harm, and loss of customers or sales.
• Operating results may fluctuate significantly, making future results difficult to predict and potentially causing them to fall below expectations.
• The sizes of the markets for current and future products have not been established with precision and may be smaller than estimated or decline, especially if the overall rate of smokers continues to decrease.
• Expectation to require substantial additional capital to finance planned operations, which may include future equity and debt financings, and this capital may not be available on acceptable terms or at all.
• Products and operations are subject to extensive government regulation and oversight both in the United States and abroad, and failure to obtain and maintain necessary regulatory approvals or delays could negatively affect the business.
• Potential involvement in intellectual property litigation, infringement claims, or administrative proceedings could be costly and interfere with the ability to sell and market products.
• Dependence on a limited number of single-source suppliers makes the company vulnerable to supply shortages and price fluctuations.
• Use of the solution requires appropriate physician training, and inadequate training may lead to negative patient outcomes and negatively affect business.
• Potential liability related to the privacy of health information obtained, subject to HIPAA and other data privacy laws, could lead to regulatory investigations or actions.
• Risk of product liability claims that would be expensive, divert management's attention, and harm reputation, with potentially inadequate insurance coverage.
• Indebtedness may limit operational flexibility and negatively affect business, financial condition, results of operations, and competitive position.
• The industry is highly competitive, and the company may not be able to compete successfully with larger companies or those with more established products or greater resources.
• Inability to manage anticipated growth in organization size could negatively affect business, financial condition, and results of operations.
• Significant changes or developments in U.S. and international laws or policies, including trade policies and tariffs, could have a material adverse effect.
• Unfavorable global economic conditions, including as a result of geopolitical conflict, could negatively affect business, financial condition, or results of operations.
• Collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships with third parties may not result in commercially viable products or significant future revenues.
• Inability to achieve or maintain satisfactory pricing and margins for products due to price competition could negatively affect business.
• Governmental export or import controls could limit ability to compete in foreign markets and subject the company to liability if violated.
• Public health crises have in the past and may in the future have a material adverse impact on business, financial condition, and results of operations.
• Potential natural disasters could damage, destroy, or disrupt clinical study sites, office spaces, manufacturing facilities, and/or warehouses, significantly impacting operations.
• Failure to comply with post-marketing regulatory requirements could subject the company to enforcement actions, including substantial penalties, and might require product recall or withdrawal.
• If treatment guidelines for severe emphysema or the standard of care evolves, the company may need to redesign and seek new marketing authorization for products.
• Misuse or off-label use of the solution could harm image, result in injuries leading to product liability suits, or costly investigations and sanctions by regulatory bodies.
• Potential for regulatory or enforcement actions if the company engages in improper marketing or promotion of its products.
• The clinical trial process required to obtain regulatory approvals and certification is lengthy and expensive with uncertain outcomes.
• Products may cause or contribute to adverse medical events or be subject to failures or malfunctions that require reporting to regulatory authorities, with failure to do so leading to sanctions.
• Failure to obtain and maintain international regulatory registrations, certification, or approvals for products would prevent marketing and sales outside the United States.
• Healthcare reform measures could hinder or prevent the commercial success of solutions.
• Employees, consultants, and other commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
• Compliance with environmental laws and regulations could be expensive, and failure to comply could subject the company to significant liability.
• Changes in patent law could diminish the value of patents in general, thereby impairing the ability to protect existing and future products.
• The failure of third parties to meet their contractual, regulatory, and other obligations could adversely affect the business.
• If trademarks and tradenames are not adequately protected, the company may not be able to build name recognition in its markets, and business may be adversely affected.
• Patent terms may not be able to protect the competitive position for an adequate period of time with respect to current or future technologies.
• Potential for claims of misappropriation of intellectual property of a third party, or breach of non-competition/non-solicitation agreements, or claims of ownership interest in company's intellectual property.

Future Outlook

Management expects to continue incurring net losses for the next several years and will require substantial additional funding, potentially through future equity and debt financings. The company plans significant investments in sales and marketing, R&D for next-generation products, and clinical studies, including the CONVERT II pivotal trial for the AeriSeal System. Existing cash and cash equivalents are expected to fund operations for at least the next 12 months.

Management Comments

• Management believes that the Company's existing cash and cash equivalents will allow the Company to continue its planned operations for at least the next 12 months from the date of the issuance of these unaudited interim condensed consolidated financial statements.
• The failure to successfully execute this leadership transition could negatively impact our business and results of operations.

Industry Context

The company operates in a highly competitive and rapidly changing medical technology environment, focusing on severe emphysema treatment. It faces competition from established players and new technologies, with a goal to make its solution a standard of care. The declining rate of smokers globally could eventually decrease the addressable patient population for COPD and emphysema treatments. The industry is also subject to increasing scrutiny from regulatory bodies regarding interactions with healthcare providers and data privacy.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Received a civil investigative demand (CID) from the U.S. Department of Justice (USDOJ) in December 2022 regarding an investigation under the Anti-Kickback Statute and False Claims Act related to sales and marketing of Zephyr Valves.
• In March 2025, the USDOJ informed the company that its investigation was based on a Qui Tam Action and that the United States and various states were electing not to intervene or pursue the matter further.
• The company has entered into settlement discussions and recorded an estimated liability for the settlement, subject to approval by the USDOJ and other parties.

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Potential dilution from future equity raises; stock price volatility due to financial performance, market conditions, and litigation risks; reliance on stock appreciation for returns as no dividends are planned.
• Employees: Impacted by management changes, potential for increased headcount in sales/marketing and R&D, and stock-based compensation.
• Customers (Hospitals/Physicians): Continued efforts to increase adoption of Zephyr Valve, training requirements, and reimbursement policies are critical.
• Patients: Access to Zephyr Valve treatment depends on physician adoption, reimbursement, and ongoing clinical trials for new products like AeriSeal System.
• Suppliers: Reliance on single-source suppliers creates vulnerability to supply shortages and price fluctuations.
• Creditors: Indebtedness under CIBC Loan and Credit Agreement, with covenants that limit company flexibility.

Next Steps

• Continue to make significant investments in sales and marketing organization throughout the United States, Europe, and Asia Pacific.
• Continue to make investments in research and development efforts to develop next-generation products and support future regulatory submissions.
• Continue progress with the CONVERT II pivotal trial of the AeriSeal System.
• Seek additional funding through public or private equity offerings, debt financings, and collaborations or licensing arrangements.
• Complete conformity assessment procedures for medical devices in accordance with the MDR prior to the expiration of existing CE Certificates of Conformity.

Key Dates

Recommendation

While Pulmonx demonstrated revenue growth and improved gross margin in the recent quarter, the company continues to incur substantial net losses and negative cash flow from operations, leading to a significant accumulated deficit. The extension of the CIBC loan's interest-only period provides some near-term liquidity relief, and the USDOJ's decision not to intervene in the Qui Tam action removes a significant legal overhang. However, the company explicitly states the need for substantial additional capital in the future, which could lead to further shareholder dilution. The competitive landscape, regulatory complexities, and reliance on a single primary product for a limited indication present ongoing risks. Given these mixed signals, a 'hold' recommendation is appropriate, suggesting investors monitor the company's progress in achieving profitability, securing additional funding on favorable terms, and expanding its product pipeline and market adoption.

Keywords

Pulmonx, Zephyr Valve, Emphysema, COPD, Medical Technology, LungTraX Platform, Chartis System, Endobronchial Valve, Financial Results, Q3 2025, SEC Filing, 10-Q, Medical Device, Healthcare, Respiratory, Clinical Trials, AeriSeal System, Corporate Governance, Debt Financing, Reimbursement, Intellectual Property